scholarly journals Adipokines in Insulin Resistance: Current Updates

2021 ◽  
Vol 18 (2) ◽  
pp. 357-366
Author(s):  
Utpal Jagdish Dongre

Obesity is a chronic metabolic disease that affects both the pediatric and adult populations. Adipose tissue acts as an endocrine organ which secretes various adipokines involved in fat mass regulation and energy balance via modulating the metabolic signalling pathways. Altered secretion of adipokines promotes multiple complications, including insulin resistance. The primary mechanism of action that underlines the involvement of adipokines in the development of insulin resistance includes phosphorylation/de-phosphorylation of insulin receptor substrate-1 (IRS-1) facilitate by other signalling molecules like a suppressor of cytokine signalling 1 (SOCS-1). Adipokines mediated insulin resistance further contribute to the development of atherosclerosis, dyslipidemia, fatty liver disease, cancer etc. Thus, this review provides recent updates on the role of resistin, lipocalin-2, RBP-4, chemerin, TNF-alpha and IL-6 adipokines in the progression of insulin resistance.

2009 ◽  
Vol 55 (6) ◽  
pp. 40-45 ◽  
Author(s):  
Viktor Shvarts

Obesity is a factor contributing to the development of atherosclerosis and cardiovasular diseases. A key pathogenetic mechanism of obesity-associated atherosclerosis is inflammation of the adipose tissue concomitant with mild systemic inflammation, altered secretion of adipokines and cytokines, and insulin resistance. This review is focused on the role of hypoadiponectinemia, enhanced secretion of leptin, resistin, TNF-alpha, IL-1, IL-6, interferon-gamma, and activation of renin-angiotensin system in pathogenesis of atherosclerosis. The stimulatory action of insulin resistance accompanying inflammation of the adipose tissue on evolution of atherosclerosis is mediated through the development of dyslipidemia, hyperglycemia, and arterial hypertension. Other important factors involved in pathogenetic mechanisms of atherosclerosis are inflammation of perivascular fatty tissue and paracrine activity of cytokines and chemokines it releases.


2020 ◽  
Author(s):  
Victoria Liedtke ◽  
Christian Schröder ◽  
Dirk Roggenbuck ◽  
Romano Weiss ◽  
Ralf Stohwasser ◽  
...  

Abstract BackgroundLens epithelium derived growth factor splice variant of 75 kDa (LEDGF/p75), is overexpressed in different solid cancers and cancer cell lines and various autoinflammatory diseases. Due to its ability to bind chromatin, it acts as a transcriptional co-activator and promotes anti-apoptotic signalling pathways that lead to increased tumour aggressiveness and resistance to chemotherapy. The role of LEDGF/p75 in DNA-damage repair (DDR) is still not completely elucidated particularly regarding the ubiquitin-dependent regulation and degradation of DDR signalling molecules.MethodsDifferent LEDGF model cell lines were generated, a complete knock-out of LEDGF (KO) as well as the re-expression of LEDGF/p75 or LEDGF/p52 using CRISPR/Cas9 technology. Then, various assays were performed to determine their proliferation and migration capacity as well as their chemosensitivity. Moreover, DDR signalling pathways were investigated by western blot and immunofluorescence.ResultsLEDGF-deficient cells exhibited a decreased proliferation (dt (WT) = 21 h, dt (KO) = 26 h) , 60 % decreased migration, as well as an 30-50 % increased sensitivity towards the topoisomerase II inhibitor etoposide. Moreover, LEDGF depleted cells showed a significant reduction by 65 % in the recruitment of downstream DDR-related proteins like replication protein A 32 kDa subunit (RPA32) after exposure to etoposide. Re-expression of LEDGF/p75 rescued all knock-out effects, while re-expression of LEDGF/p52 had no effect.Surprisingly, untreated LEDGF KO cells showed an increased amount of DNA fragmentation combined with an increased formation of γH2AX and Breast cancer type 1 susceptibility protein (BRCA1). In contrast, the protein levels of ubiquitin-conjugating enzyme UBC13 and nuclear proteasome activator PA28γ were substantially reduced upon LEDGF KO. ConclusionsThis study provides evidence that LEDGF is not only an important player in the DDR after chemotherapeutic treatments but is also involved in the maintenance of the general genome integrity. Moreover, this study provides for the first time an insight into the possible role of LEDGF in the ubiquitin-dependent regulation of DDR signalling molecules and highlights the involvement of LEDGF/p75 in homology-directed DNA repair.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 285-LB ◽  
Author(s):  
KARTHICKEYAN CHELLA KRISHNAN ◽  
SIMON SABIR ◽  
RAQUEL FLOYD ◽  
DULSHAN JAYASEKERA ◽  
ALDONS LUSIS

2018 ◽  
Vol 61 (1) ◽  
pp. 37-45 ◽  
Author(s):  
Tae Woo Jung ◽  
Yoon Hee Chung ◽  
Hyoung-Chun Kim ◽  
A M Abd El-Aty ◽  
Ji Hoon Jeong

Leukocyte cell-derived chemotaxin 2 (LECT2) is a recently identified novel hepatokine that causes insulin resistance in skeletal muscle by activating c-Jun N-terminal kinase (JNK), thereby driving atherosclerotic inflammation. However, the role of LECT2 in inflammation and insulin resistance in adipocytes has not been investigated. In this study, we report that LECT2 treatment of differentiated 3T3-L1 cells stimulates P38 phosphorylation in a dose-dependent manner. LECT2 also enhanced inflammation markers such as IκB phosphorylation, nuclear factor kappa beta (NF-κB) phosphorylation and IL-6 expression. Moreover, LECT2 treatment impaired insulin signaling in differentiated 3T3-L1 cells, as evidenced by the decreased levels of insulin receptor substrate (IRS-1) and Akt phosphorylation and reduced insulin-stimulated glucose uptake. Furthermore, LECT2 augmented lipid accumulation during 3T3-L1 cell differentiation by activating SREBP1c-mediated signaling. All these effects were significantly abrogated by siRNA-mediated silencing of P38, CD209 expression or a JNK inhibitor. Our findings suggest that LECT2 stimulates inflammation and insulin resistance in adipocytes via activation of a CD209/P38-dependent pathway. Thus, these results suggest effective therapeutic targets for treating inflammation-mediated insulin resistance.


2003 ◽  
Vol 31 (6) ◽  
pp. 1445-1446 ◽  
Author(s):  
X. Li ◽  
L. Wheldon ◽  
J.K. Heath

Sprouty was first identified in Drosophila as a novel antagonist of the fibroblast growth factor signalling pathway. Sprouty proteins comprise a big family, members of which are characterized by a cysteine-rich domain which confers inhibitory activity, whereas differences in the N-terminal region may be responsible for functional divergence. The role of Sprouty in RTK (receptor tyrosine kinase) signalling pathways is still controversial. Sprouty may negatively or positively regulate RTK signalling via differential interaction with different signalling molecules, and hence exert different mechanism of action.


2001 ◽  
Vol 345 (18) ◽  
pp. 1345-1346 ◽  
Author(s):  
Alan R. Shuldiner ◽  
Rongze Yang ◽  
Da-Wei Gong

2011 ◽  
Vol 165 (5) ◽  
pp. 703-711 ◽  
Author(s):  
Primoz Kotnik ◽  
Pamela Fischer-Posovszky ◽  
Martin Wabitsch

Adipose tissue is an endocrine organ secreting biologically active factors called adipokines that act on both local and distant tissues. Adipokines have an important role in the development of obesity-related comorbidities not only in adults but also in children and adolescents. Retinol binding protein 4 (RBP4) is a recently identified adipokine suggested to link obesity with its comorbidities, especially insulin resistance, type 2 diabetes (T2D), and certain components of the metabolic syndrome. However, data, especially resulting from the clinical studies, are conflicting. In this review, we summarize up-to-date knowledge on RBP4's role in obesity, development of insulin resistance, and T2D. Special attention is given to studies on children and adolescents. We also discuss the role of possible confounding factors that should be taken into account when critically evaluating published studies or planning new studies on this exciting adipokine.


2020 ◽  
Vol 20 (2) ◽  
pp. 103-109 ◽  
Author(s):  
Leandro B. Bergantin

Background: A correlation between cognitive dysfunctions and brain insulin resistance has been established by several clinical and experimental studies. Consistent data support that people diagnosed with brain insulin resistance, resulted from diabetes, have shown an increased risk of presenting cognitive dysfunctions, clinical signs of dementia and depression, then speculating a role of dysregulations related to insulin signalling in these diseases. Furthermore, it is currently discussed that Ca2+ signalling, and its dysregulations, may be a factor which could correlate with brain insulin resistance and cognitive dysfunctions. Objective: Following this, revealing this interplay between these diseases may provide novel insights into the pathogenesis of such diseases. Methods: Publications covering topics such as Ca2+ signalling, diabetes, depression and dementia (alone or combined) were collected by searching PubMed and EMBASE. Results: The controlling of both neurotransmitters/hormones release and neuronal death could be achieved through modulating Ca2+ and cAMP signalling pathways (Ca2+/cAMP signalling). Conclusion: Taking into account our previous reports on Ca2+/cAMP signalling, and considering a limited discussion in the literature on the role of Ca2+/cAMP signalling in the link between cognitive dysfunctions and brain insulin resistance, this article has comprehensively discussed the role of these signalling pathways in this link (between cognitive dysfunctions and brain insulin resistance).


Sign in / Sign up

Export Citation Format

Share Document